Hansa Biopharma Presents Positive Idefirix Clinical Data at ASN Kidney Week
What happened
Hansa Biopharma announced the presentation of data from the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado. The study involved 50 Idefirix crossmatch-positive deceased-donor kidney transplants in Europe. The results showed a 1-year graft failure-free survival rate of 90%, with graft survival at 92% and patient survival at 98%.
From prnewswire.com
Why it matters
The presentation highlights the potential of imlifidase to address a significant unmet need for highly sensitized patients awaiting kidney transplantation. Hansa Biopharma's product, Idefirix, is currently under conditional authorization by the European Commission.
From prnewswire.com
Who's involved
- Hansa BiopharmaPresented PAES study data on Idefirix at the conference.
- American Society of NephrologyHosted the conference where Hansa Biopharma presented its clinical findings.
Keep exploring
The entities involved
-
Hansa Biopharma
company in Lund, Sweden
Nothing else this week.
-
American Society of Nephrology
organization
Nothing else this week.